Table 4 Usefulness of the medication surveillance program in a clinical setting per total respondents: physicians and pharmacists
Medication surveillance program | Frequency (%) | p-value | ||||
|---|---|---|---|---|---|---|
Very un-useful | Somewhat un-useful | Neutral | Somewhat useful | Very useful | ||
Drug–drug interaction | 11 (1.0) | 49 (4.4) | 133 (12.0) | 299 (26.9) | 618 (55.7) | < 0.001 |
Physicians | 10 (2.0) | 34 (6.8) | 64 (12.9) | 161 (32.4) | 228 (45.9) | |
Pharmacists | 1 (0.2) | 15 (2.4) | 69 (11.3) | 138 (22.5) | 390 (63.6) | |
Age contraindication: Pediatric, Elderly | 20 (1.8) | 59 (5.3) | 226 (20.4) | 361 (32.5) | 444 (40.0) | < 0.001 |
Physicians | 17 (3.4) | 39 (7.8) | 129 (26.0) | 166 (33.4) | 146 (29.4) | |
Pharmacists | 3 (0.5) | 20 (3.3) | 97 (15.8) | 195 (31.8) | 298 (48.6) | |
Pregnancy contraindication | 28 (2.5) | 58 (5.2) | 198 (17.9) | 295 (26.7) | 526 (47.6) | < 0.001 |
Physicians | 24 (4.9) | 38 (7.7) | 101 (20.4) | 143 (28.9) | 188 (38.1) | |
Pharmacists | 4 (0.7) | 20 (3.3) | 97 (15.9) | 152 (24.9) | 338 (55.3) | |
Therapeutic duplication | 18 (1.6) | 76 (6.9) | 245 (22.2) | 361 (32.6) | 406 (36.7) | < 0.001 |
Physicians | 17 (3.4) | 45 (9.1) | 131 (26.5) | 172 (34.8) | 129 (26.1) | |
Pharmacists | 1 (0.2) | 31 (5.1) | 114 (18.6) | 189 (30.9) | 277 (45.3) | |